

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
08 May 2025 (08.05.2025)



(10) International Publication Number
WO 2025/093870 A1

(51) International Patent Classification:

C07D 519/00 (2006.01) A61P 25/28 (2006.01)
A61P 3/10 (2006.01) A61P 29/00 (2006.01)
A61P 25/00 (2006.01) A61P 35/00 (2006.01)
A61P 25/16 (2006.01) A61K 31/519 (2006.01)
A61P 25/24 (2006.01)

(21) International Application Number:

PCT/GB2024/052760

(22) International Filing Date:

30 October 2024 (30.10.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2316595.4 30 October 2023 (30.10.2023) GB

(71) Applicant: **STORM THERAPEUTICS LTD** [GB/GB];
Moneta Building, Babraham Research Campus, Cambridge
Cambridgeshire CB22 3AT (GB).

(72) Inventors: **BAYLE, Elliott David**; c/o STORM Therapeutics Ltd, Moneta Building, Babraham Research Campus, Cambridge Cambridgeshire CB22 3AT (GB). **THOMAS, Elizabeth Jane**; c/o STORM Therapeutics Ltd, Moneta Building, Babraham Research Campus, Cambridge Cambridgeshire CB22 3AT (GB). **SHEPHERD, Jon**; c/o Evotec, 114 Innovation Drive, Milton Park, Milton, Abingdon Oxfordshire OX14 4RZ (GB). **RIDGILL, Mark Peter**; c/o Evotec, 114 Innovation Drive, Milton Park, Milton, Abingdon Oxfordshire OX14 4RZ (GB).

(74) Agent: **HGF LIMITED**; 1 City Walk, Leeds, West Yorkshire LS11 9DX (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to the identity of the inventor (Rule 4.17(i))
— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

(54) Title: INHIBITORY COMPOUNDS

(57) Abstract: The present invention relates to compounds of formula (I) that function as inhibitors of METTL3 (N6-adenosine-methyltransferase 70 kDa subunit) enzyme activity, wherein Formula (I) is as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, disorders of the central nervous system and autoimmune diseases, as well as other diseases or conditions in which METTL3 activity is implicated.



WO 2025/093870 A1